About DXB
A clinical-stage biopharmaceutical company developing DMX-200 for FSGS kidney disease and DMX-700 for orphan respiratory and renal conditions, underpinned by its proprietary Receptor-HIT drug discovery platform.
All News for DXB
No news articles found for DXB yet.